Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment-Reference-Cited by-同舟云学术

Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment

Published:2015-08-28 Issue:10 Volume:4 Page:e1040214
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Le Noci Valentino¹,Tortoreto Monica²,Gulino Alessandro³,Storti Chiara⁴,Bianchi Francesca¹,Zaffaroni Nadia²,Tripodo Claudio³^ORCID,Tagliabue Elda⁴^ORCID,Balsari Andrea¹⁴^ORCID,Sfondrini Lucia¹^ORCID

Affiliation:

1. Dipartimento di Scienze Biomediche per la Salute; Università degli Studi di Milano; Milan, Italy

2. Molecular Pharmacology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy

3. Dipartimento PRO.SA.MI; Unità di Immunologia dei Tumori; Universita degli Studi di Palermo; Palermo, Italy

4. Molecular Targeting Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2015.1040214

Reference34 articles.

1. Toll-like receptor agonists in cancer therapy

2. Twelve immunotherapy drugs that could cure cancers

3. Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

4. Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma

5. Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Defined TLR3 Agonist, Nexavant, Exhibits Anti-Cancer Efficacy and Potentiates Anti-PD-1 Antibody Therapy by Enhancing Immune Cell Infiltration;Cancers;2023-12-08

2. The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration;2023-10-30

3. The Lung Microbiome in Carcinogenesis and Immunotherapy Treatment;The Cancer Journal;2023-03

4. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview;Biomedicines;2022-12-27

5. Toll-like receptor-targeted anti-tumor therapies: Advances and challenges;Frontiers in Immunology;2022-11-21